MONET1-MOtesanib NSCLC Efficacy and Tolerability Study
Stopped Amgen discontinued the development of AMG706 because 20050201 did not meet its primary objective.
Conditions
- Non-Small Cell Lung Cancer
Interventions
- DRUG: AMG 706
- DRUG: placebo
- DRUG: paclitaxel
- DRUG: carboplatin
Sponsor
Amgen
Collaborators